In September 2013, the FDA began allocating $20 million to the quality testing of generic drugs across the US. Previously, generic drug testing was only performed occasionally in the US due to limited resources. However, new fees collected from the generic drug industry have enabled the FDA to undertake large scale quality control efforts. The program began without any public notice, but FDA officials recently confirmed that at least a dozen academic centers are participating in a testing program that will run through 2017. Research this year will focus on heart drugs, ADHD treatments, immunosuppressants, anti-seizure medicines, and antidepressants.